Zydus Lifesciences (previously Cadila Healthcare) said that its subsidiary Zydus Pharmaceuticals (USA) Inc. has launched Topiramate Extended-Release Capsules in the US.

The launch follows the final approval received by Zydus Pharmaceuticals (USA) from the US Food and Drug Administration (FDA) for marketing Topiramate Extended-Release Capsules, USP 25 mg, 50 mg, and 100 mg.

The approved product is the generic of Trokendi XR (topiramate), a carbonic anhydrase inhibitor indicated for the treatment of epilepsy and the prevention of migraines.

According to IQVIA data, the annual sales of Topiramate Extended-Release capsule in the US was $488 million.

  Cadila Healthcare, Epilepsy, Migraine, topiramate, Trokendi XR, USA, Zydus Lifesciences, Zydus Pharmaceuticals (USA)